Ixekizumab Improves Patient-Reported Outcomes in Non-Radiographic Axial Spondyloarthritis: Results from the Coast-X Trial

INTRODUCTION: Ixekizumab, an interleukin-17A antibody, has shown efficacy in non-radiographic axial spondyloarthritis (nr-axSpA). The objectives of this analysis were (a) to measure improvement in ixekizumab-treated patients in Assessment of Spondyloarthritis International Society (ASAS) response do...

Descripción completa

Detalles Bibliográficos
Autores principales: Deodhar, Atul, Mease, Philip, Rahman, Proton, Navarro-Compán, Victoria, Marzo-Ortega, Helena, Hunter, Theresa, Sandoval, David, Kronbergs, Andris, Leon, Luis, Shan, Mingyang, Leung, Ann, De Vlam, Kurt, Strand, Vibeke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7991024/
https://www.ncbi.nlm.nih.gov/pubmed/33284423
http://dx.doi.org/10.1007/s40744-020-00254-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7991024/
https://www.ncbi.nlm.nih.gov/pubmed/33284423
http://dx.doi.org/10.1007/s40744-020-00254-z

Ejemplares similares